Needham analyst Mayank Tandon downgrades BTRS Holdings (NASDAQ:BTRS) from Buy to Hold.
Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation Of Cell Proliferation Signals In Pre-Clinical Models; Shares Halted On Circuit Breaker To The Upside
--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE" --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN
